Log In
BCIQ
Print this Print this
 

AD-4833/TOMM40

  Manage Alerts
Collapse Summary General Information
Company Takeda Pharmaceutical Co. Ltd.
DescriptionInsulin sensitizer/biomarker assay
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics: Biomarkers and companion diagnostics
Latest Stage of DevelopmentPhase III
Standard IndicationAlzheimer's disease (AD)
Indication DetailsDelay the onset of mild cognitive impairment (MCI) due to Alzheimer's disease (AD)
Regulatory Designation
PartnerZinfandel Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$9.0M

0


 Deals Details
Get a free BioCentury trial today